GCP
PHAT icon

GSA Capital Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

GSA Capital Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
97,068
+14,444
+17% +$182K 0.07% 454
2025
Q4 		$1.37M Buy
82,624
+12,366
+18% +$177K 0.12% 208
2025
Q3 		$827K Buy
+70,258
New +$725K 0.07% 527
2025
Q1 		– Sell
-15,173
Closed -$123K – 1985
2024
Q4 		$123K Buy
15,173
+90
+0.6% +$1.11K 0.01% 1498
2024
Q3 		$273K Sell
15,083
-14,323
-49% -$200K 0.02% 1267
2024
Q2 		$303K Buy
29,406
+15,232
+107% +$157K 0.02% 1277
2024
Q1 		$151K Buy
+14,174
New +$120K 0.01% 1446
2023
Q4 		– Sell
-121,892
Closed -$1.26M – 1820
2023
Q3 		$1.26M Buy
121,892
+67,983
+126% +$933K 0.11% 290
2023
Q2 		$772K Buy
53,909
+33,677
+166% +$388K 0.08% 456
2023
Q1 		$144K Buy
20,232
+1,715
+9% +$15.1K 0.01% 1312
2022
Q4 		$208K Buy
+18,517
New +$191K 0.03% 1160
2021
Q1 		– Sell
-21,871
Closed -$727K – 1392
2020
Q4 		$727K Buy
+21,871
New +$886K 0.12% 234

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

GSA Capital Partners's PHAT Position: Q1 2026 in Review

GSA Capital Partners increased its Phathom Pharmaceuticals (PHAT) stake by 17% in Q1 2026, buying an estimated $182K and bringing the position to 97,068 shares worth $1.08M. The position accounts for 0.07% of the portfolio, ranked #454.

GSA Capital Partners first reported a position in PHAT in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.37M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • GSA Capital Partners held 97,068 shares of Phathom Pharmaceuticals worth $1.08M as of Q1 2026.
  • GSA Capital Partners bought 14,444 Phathom Pharmaceuticals shares in Q1 2026, an estimated $182K.
  • Phathom Pharmaceuticals made up 0.07% of GSA Capital Partners's portfolio in Q1 2026, its #454 holding.
  • GSA Capital Partners first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • GSA Capital Partners's Phathom Pharmaceuticals position peaked at $1.37M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.